Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun 14:14:113-121.
doi: 10.2147/OARRR.S368190. eCollection 2022.

The Clinical Impact of Seropositivity on Treatment Response in Patients with Rheumatoid Arthritis Treated with Etanercept: A Real-World Iraqi Experience

Asal Ridha  1 , Saba Hussein  2 , Ali AlJabban  3 , Levent Mert Gunay  4 , Faiq I Gorial  5 , Nizar Abdulateef Al Ani  5
Affiliations

The Clinical Impact of Seropositivity on Treatment Response in Patients with Rheumatoid Arthritis Treated with Etanercept: A Real-World Iraqi Experience

Asal Ridha et al. Open Access Rheumatol. .

Abstract

Purpose: To assess the clinical impact of rheumatoid factor (RF) and anti-cyclic citrullinated peptide antibody (ACPA)'s seropositivity on treatment response in patients with rheumatoid arthritis (RA) treated with etanercept.

Patients and methods: A retrospective analysis of patients with RA registered in Baghdad Teaching Hospital Registry from May 2012 to August 2019 was conducted. Patients aged ≥18 years, meeting the ACR/EULAR 2010 criteria for RA, being treated with etanercept, and followed up at ≥1 year after etanercept initiation were included; patients who received any other biologics for RA were excluded. Patients were classified as seropositive (RF- and ACPA-positive), seronegative (RF- and ACPA-negative), RF-positive, RF-negative, ACPA-positive, and ACPA-negative. The primary outcomes included Clinical Disease Activity Index (CDAI) and Disease Activity Score 28 (DAS28) which were measured at one year after treatment initiation.

Results: At baseline, a total of 1318 (88.3%) patients were seropositive; 1122 (75.2%) and 1054 (70.6%) patients were RF- and ACPA-positive, respectively. Baseline mean CDAI scores were significantly (P = 0.001) higher among seropositive patients compared with seronegative patients. The baseline mean DAS28 score was also significantly higher in ACPA-positive group compared with the ACPA-negative group (P = 0.021). At baseline, the number of patients who had high CDAI scores was significantly higher among the seropositive, RF-positive, and ACPA-positive groups (P = 0.001, P = 0.001, and P = 0.002, respectively). After one year of treatment with etanercept, among seropositive versus seronegative and ACPA-positive versus ACPA-negative groups, there was a significant improvement in terms of the mean CDAI score (P = 0.004 and P = 0.017, respectively) and CDAI response (P = 0.011 and P = 0.048, respectively). At one year, the proportion of patients among the seropositive versus seronegative group who reached remission were 566 (42.9%) versus 78 (44.6%) and 642 (47.3%) versus 83 (47.4%), for CDAI and DAS28 response, respectively.

Conclusion: The results imply that seropositivity and ACPA-positivity may influence the treatment response in patients with RA, who were treated with etanercept.

Keywords: Iraq; anti-cyclic citrullinated peptide antibody; real-world; rheumatoid factor.

PubMed Disclaimer

Conflict of interest statement

AR, SH, FIG, and NAA declare no conflicts of interest in this work. AA and LMG are employees of Pfizer.

Figures

Figure 1
Figure 1
Seropositivity impact on baseline CDAI, DAS28 and one year after treatment with etanercept. (A-D) Mean change in CDAI and DAS28 scores from baseline to 1 year after initiation of treatment.
See this image and copyright information in PMC

References

    1. Harrold LR, Bryson J, Lehman T, et al. Association between baseline anti-cyclic citrullinated peptide antibodies and 6-month clinical response following Abatacept or TNF inhibitor treatment: a real-world analysis of biologic-experienced patients with RA. Rheumatol Ther. 2021;8(2):937–953. doi:10.1007/s40744-021-00310-2 - DOI - PMC - PubMed
    1. Almutairi K, Nossent J, Preen D, Keen H, Inderjeeth C. The global prevalence of rheumatoid arthritis: a meta-analysis based on a systematic review. Rheumatol Int. 2021;41(5):863–877. doi:10.1007/s00296-020-04731-0 - DOI - PubMed
    1. Gabriel SE, Michaud K. Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases. Arthritis Res Ther. 2009;11(3):1–16. doi:10.1186/ar2669 - DOI - PMC - PubMed
    1. Cross M, Smith E, Hoy D, et al. The global burden of rheumatoid arthritis: estimates from the global burden of disease 2010 study. Ann Rheum Dis. 2014;73(7):1316–1322. doi:10.1136/annrheumdis-2013-204627 - DOI - PubMed
    1. Wilson D. Rheumatoid factors in patients with rheumatoid arthritis. Can Fam Physician. 2006;52(2):180. - PMC - PubMed